California to Get Low-Cost Insulin Products in 2026 After Delays

California will become the only state offering its own low-cost alternatives to brand-name insulin products starting in January, the governor announced Thursday following months of delays to the project.

The biosimilar insulin, to be sold under the state’s CalRx label, will cost no more than $11 per pen and be available beginning Jan. 1, 2026, California Gov. Gavin Newsom‘s (D) office said in a press release. The pen is being manufactured through a contract with nonprofit generic drug manufacturer Civica Rx and biosimilar manufacturer Biocon Biologics.

“California and Civica are showing the nation what it looks like to ...